TY  - JOUR
TI  - Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed
Multiple Myeloma Patients
AB  - Objective: Constantly increasing health expenditures lead to the use
of generic molecules and generic versions of bortezomib have been
used for a long time. The aim of this study is to retrospectively examine
the effectiveness, side effects, and reliability of generic bortezomib in
newly diagnosed multiple myeloma (MM) patients.
Materials and Methods: The data of 95 patients who received four
cycles of bortezomib as first- or second-line therapy in a single center
were retrospectively recorded. Treatment responses, side effects, and
progression-free survival (PFS) rates were calculated and compared.
Results: Of the 95 patients, 42 used the original and 53 used the
generic molecule. Epidemiological data, MM types, genetic risk
groups, laboratory values at diagnosis, and bortezomib treatment lines
(as a first line or second) were evaluated and there was no statistical
difference between the two groups. When the response rates were
evaluated according to International Myeloma Working Group criteria,
there was no significant difference (p=0.42). Rates of partial response
and higher responses were similar (81% vs. 79.2%, p=0.84). PFS rates
were 42.8 months with the original and 37.8 months with the generic
molecule (p=0.68). Side effects were seen in 44.2% of all patients,
and the most common side effects were neuropathy, cytopenia, and
infection. These rates were similar in the two groups (p=0.55).
Conclusion: Although this retrospective study is limited in scope, it is
the first study comparing the original molecule of bortezomib with a
generic version. There were no statistical differences between the two
groups in terms of treatment responses, PFS, or side effects. However,
large-scale evaluations will help obtain more data on this subjec
AU  - YENİHAYAT, Emel Merve
AU  - Hacıhanefioğlu, Abdullah
AU  - Tarkun, Pinar
AU  - Polat, Merve Gökçen
AU  - MEHTAP, Özgür
AU  - ALBAYRAK, Hayrunnisa
AU  - MERSİN, Sinan
AU  - Ünal, Serkan
AU  - AYGÜN, Kemal
AU  - GEDÜK, Ayfer
DO  - 10.4274/tjh.galenos.2021.2020.0555
PY  - 2021
JO  - Turkish Journal of Hematology
VL  - 38
IS  - 3
SN  - 1300-7777
SP  - 211
EP  - 217
DB  - TRDizin
UR  - http://search/yayin/detay/508992
ER  -